BCM
CNCE

Bourgeon Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bourgeon Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-30,000
Closed -$447K – 112
2015
Q2 		$447K Buy
+30,000
New +$457K 0.27% 72

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bourgeon Capital Management's CNCE Position: Q3 2015 in Review

Bourgeon Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2015, closing a stake of 30,000 shares — an estimated $447K sold.

Bourgeon Capital Management first reported a position in CNCE in Q2 2015 and held it in 1 quarter. The position peaked at $447K in Q2 2015. 90 funds tracked by Wall St. Rank hold CNCE as of Q3 2015.

  • Bourgeon Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Bourgeon Capital Management sold 30,000 Concert Pharmaceuticals, Inc. shares in Q3 2015, an estimated $447K.
  • Bourgeon Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Bourgeon Capital Management's Concert Pharmaceuticals, Inc. position peaked at $447K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2015.

Based on Bourgeon Capital Management's 13F filing for Q3 2015, filed 2 Nov 2015.